PMC4428504_01
Computing tomography scan showing multifocal abnormalities, involving both lobes of the liver. The uninvolved portions of hepatic parenchyma underwent relative hypertrophy. No calcification was visible initially. In the left liver, lesions coalesce, forming a diffuse pattern. So the target lesion was chosen in the right liver, initially measuring 138 x 146 mm, extending to the capsular margin with areas of retraction. After administration of IV contrast material, this main nodule displayed marginal enhancement during the portal phase. Inferior vena cava was compressed but remained permeable.
13569_2014_18_Fig1_HTML.jpg
PMC4428504_01_13569_2014_18_Fig1_HTML.jpg
Fig1
CT scan assessment after 3 months demonstrated stable hepatic and pulmonary disease (Figure 1).
Chest scanner of November 2007 showing micronodular pulmonary lesions.
13569_2014_18_Fig2_HTML.jpg
PMC4428504_01_13569_2014_18_Fig2_HTML.jpg
Fig2
Tumors criteria v. 1.0,10, tumor response consisted in a prolonged stabilization (Figures 2, 3 and 4). Importantly an ectasia of the thoracic was noted on the most recent echocardiography, this anomaly will be carefully monitored. The role of pazopanib in this phenomenon observed after 8 years of treatment remains unclear but should prompt further investigations in long term survivors under VEGFR2 inhibitors including pazopanib.
CT scanner of April 2014 showing that the appearance and size of the main lesion remained similar. The target lesion measured 126*137 mm and peripheric calcifications had appeared confirming radiological tumoral control.
13569_2014_18_Fig3_HTML.jpg
PMC4428504_01_13569_2014_18_Fig3_HTML.jpg
Fig3
Tumors criteria v. 1.0,10, tumor response consisted in a prolonged stabilization (Figures 2, 3 and 4). Importantly an ectasia of the thoracic was noted on the most recent echocardiography, this anomaly will be carefully monitored. The role of pazopanib in this phenomenon observed after 8 years of treatment remains unclear but should prompt further investigations in long term survivors under VEGFR2 inhibitors including pazopanib.
Chest scanner of October 2014 showing stable aspect of lung micronuodules.
13569_2014_18_Fig4_HTML.jpg
PMC4428504_01_13569_2014_18_Fig4_HTML.jpg
Fig4
Tumors criteria v. 1.0,10, tumor response consisted in a prolonged stabilization (Figures 2, 3 and 4). Importantly an ectasia of the thoracic was noted on the most recent echocardiography, this anomaly will be carefully monitored. The role of pazopanib in this phenomenon observed after 8 years of treatment remains unclear but should prompt further investigations in long term survivors under VEGFR2 inhibitors including pazopanib.